Spectral Diagnostics Closes $5.6 Million Offering

- Toray Industries, Inc. Subscribes for $5 Million of Offering - 
TORONTO, April 2, 2013 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: 
DIAGF) ("Spectral", or the "Company") and Toray Industries, Inc. ("Toray") 
today announced the completion of the previously announced $5.6 million 
private placement of the Company, comprised of a total of 18,666,667 common 
shares in the capital of the Company ("Common Shares"), at a price of $0.30 
per Common Share (the "Private Placement"). 
Toray acquired 16,666,667 Common Shares in the Private Placement, at a price 
of $0.30 per Common Share, for $5 million. Following completion of the 
Private Placement, Toray's 16,666,667 Common Shares represent approximately 
12.6% of the issued and outstanding Common Shares, calculated on a non-diluted 
basis 
"We are very pleased to have Toray as a shareholder and we sincerely 
appreciate the support of existing investors who participated in this offering 
at a premium to market. This is indicative of the confidence that they have in 
our clinical development program and prospects for Toraymyxin in the U.S. 
market," said Anthony Businskas, Executive Vice President and CFO of Spectral. 
"This strategic investment not only provides additional funds for the clinical 
trial, but also strengthens the existing collaborative relationship we have 
with Spectral. Toray will work with Spectral to complete the clinical study 
for U.S. FDA market approval of Toraymyxin and together we hope to accelerate 
the launch of this product into the U.S. market," said Kazuhiro Maruyama, 
Senior Vice President of Toray. 
The net proceeds of the Private Placement will be used to continue to support 
the Company's Phase III EUPHRATES clinical trial and for general corporate 
purposes. 
The acquisition of the Common Shares by Toray was made for investment purposes 
only, and not with the purpose of influencing control or direction over 
Spectral. Toray may acquire further Common Shares, or dispose of its 
holdings of Common Shares, as investment conditions warrant. 
About Spectral Diagnostics 
Spectral is a Phase III company seeking U.S. FDA approval for its lead 
theranostics product (Toraymyxin) for the treatment of septic shock. 
Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which 
can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin 
Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk of 
developing sepsis, Spectral's EUPHRATES trial is the world's first 
theranostics trial in the area of sepsis. 
Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on 
the OTC QX under the symbol DIAGF. For more information please visit 
www.spectraldx.com 
About Toray Industries, Inc. 
Toray Industries, Inc. is a Japanese-based manufacturer of fibers, textiles, 
plastics, chemicals, IT related products, carbon fiber composite materials, 
environmental and engineering equipment, and pharmaceutical and medical 
products. In FY 2011, Toray was active in 23 countries and regions, and had 
net sales of ¥1.6 trillion (approximately U.S.$19 billion). Toray 
manufactures the Toraymyxin hemoperfusion device and has licensed to Spectral 
the exclusive commercialisation rights to this product in the United States 
and granted the Company exclusive distribution rights in Canada. 
Note: U.S. dollar amounts have been converted from yen at the exchange rate of 
¥82.2 = U.S.$1, the approximate rate of exchange prevailing on March 31, 2012. 
Forward-looking statement 
Information in this news release that is not current or historical factual 
information may constitute forward looking information within the meaning of 
securities laws. Implicit in this information, particularly in respect of the 
future outlook of Spectral and anticipated events or results, are assumptions 
based on beliefs of Spectral's senior management as well as information 
currently available to it. While these assumptions were considered reasonable 
by Spectral at the time of preparation, they may prove to be incorrect. 
Readers are cautioned that actual results are subject to a number of risks and 
uncertainties, including the availability of funds and resources to pursue R&D 
projects, the successful and timely completion of clinical studies, the 
ability of Spectral to take advantage of business opportunities in the 
biomedical industry, the granting of necessary approvals by regulatory 
authorities as well as general economic, market and business conditions, and 
could differ materially from what is currently expected. 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this statement. 
Spectral Diagnostics Inc. 
Anthony Businskas Executive Vice President and CFO 416-626-3233 ext. 2200 
Adam Peeler Investor Relations 416-815-0700 ext. 225 apeeler@tmxequicom.com 
SOURCE: Spectral Diagnostics Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2013/02/c9626.html 
CO: Spectral Diagnostics Inc.
ST: Ontario
NI: BTC CPR ELE NEWSTK  
-0- Apr/02/2013 11:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.